Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women

International Journal of Obesity volume 28, pages 1059–1063 (2004)Cite this article

Abstract

BACKGROUND AND AIM: Orlistat and metformin are the currently used drugs for weight loss. We aimed to compare the effect of orlistat and orlistat plus metformin combination therapy on weight loss and insulin resistance in obese women.

PATIENTS AND METHODS: In all, 57 obese women (body mass index ≥30 kg/m2 and normal glucose tolerance) were included. All subjects took the same content and caloric diet therapy during the study. After a month of diet period, each individual was randomly assigned to receive 360 mg orlistat per day (group 1; n=30) or 360 mg orlistat plus 1700 mg metformin per day (group 2; n=27) during the next 3 months. Body weight and insulin resistance by the homeostasis model assessment model (HOMA-IR) was measured at baseline, first month and fourth month.

RESULTS: The mean weight loss in groups 1 and 2 was 1.36±0.8 kg (1.4±0.7%) and 1.11±0.7 kg (1.1±0.7%) from baseline to first month; 4.8±2.9 kg (5.28±3.0%) and 5.77±2.5 kg (6.17±2.9%) from first month to fourth month. Body weight was decreased in groups 1 (P< 0.001) and 2 (P< 0.001), but there was no statistically significant difference between groups. Change of HOMA-IR in groups 1 and 2 was 0.41±0.4 (14.9±10.1%) and 0.23±0.7 (8.16±12.3%) from baseline to first month; 0.49±0.77 (22.0±26%) and 0.95±0.88 (34.8±29.1%) from first month to fourth month. HOMA-IR value was decreased in groups 1 (P< 0.001) and 2 (P< 0.001) but was not different between groups during the study period.

CONCLUSIONS: Combination of orlistat with metformin did not result in an additional effect on weight loss and insulin resistance when compared to orlistat alone in our study. However, new studies which have more sample sizes and the longer study period are necessary for this purpose.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Larsson B, Björntorp P, Tibblin G . The health consequences of moderate obesity. Int J Obes Relat Metab Disord 1981; 5: 97–106.

    CAS  Google Scholar 

  2. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DS, Hankinson S, Hennekens CH, Speizar FE . Body weight and mortality among women. N Engl J Med 1995; 333: 677–684.

    Article  CAS  Google Scholar 

  3. Pi-Sunyer FX . A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996; 18: 1006–1036.

    Article  CAS  Google Scholar 

  4. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjöstrom L . Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Int Med 2000; 160: 1321–1326.

    Article  CAS  Google Scholar 

  5. Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, So WY, Ma RC, Ozaki R, Woo J, Cockram CS, Chan JC . The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Int Med 2002; 162: 2428–2435.

    Article  CAS  Google Scholar 

  6. Goldstein DJ . Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397–415.

    CAS  Google Scholar 

  7. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C . Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol 1995; 141: 1128–1141.

    Article  CAS  Google Scholar 

  8. Williamson DF, Serdula MK, Anda RF, Levy A, Byers T . Weight loss attempts in adults: goals, duration and rate of weight loss. Am J Public Health 1992; 82: 1251–1257.

    Article  CAS  Google Scholar 

  9. Miller WC, Koceja DM, Hamilton EJ . A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes Relat Disord 1997; 21: 941–947.

    Article  CAS  Google Scholar 

  10. Garrow JS, Summerbell CD . Meta-analysis: effect of exercise, with or without dieting, on the body composition of overweight subjects. Eur J Clin Nutr 1995; 49: 1–10.

    CAS  Google Scholar 

  11. Foster GD, Wadden TA, Vogt RA . What is reasonable weight loss?: patients’expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997; 65: 79–85.

    Article  CAS  Google Scholar 

  12. Van Gaal LF, Broom JI, Enzi G, Toplak H . Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998; 54: 125–132.

    Article  CAS  Google Scholar 

  13. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S . Effects of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123–1128.

    Article  CAS  Google Scholar 

  14. Gokcel A, Gumurdulu Y, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N . Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4: 49–55.

    Article  CAS  Google Scholar 

  15. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA . Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10: 642–650.

    Article  CAS  Google Scholar 

  16. Unluhızarcı K, Kelestimur F, Sahin Y, Bayram F . The treatment of insulin resistance does not improve adrenal cytochrome P450c17α enzyme dysregulation in polycystic ovary syndrome. Eur J Endocrinol 1999; 140: 56–61.

    Article  Google Scholar 

  17. Diamanti-Kandarakis E, Kouli C, Tsianeteli T, Bergiele A . Therpeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138: 269–274.

    Article  CAS  Google Scholar 

  18. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ . Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647–654.

    Article  CAS  Google Scholar 

  19. Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L, Cox C . Long-term weight control study I (weeks 0–34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine vs placebo. Clin Pharmacol Ther 1992; 51: 586–594.

    Article  CAS  Google Scholar 

  20. Bray GA, Greenway FL . Current and potential drugs for treatment of obesity. Endocr Rev 2000; 20: 805–875.

    Article  Google Scholar 

  21. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report (review). Obesity Res 1998; (Suppl 2): 51S–209S.

  22. DeFronzo RA, Ferrannini E . Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–194.

    Article  CAS  Google Scholar 

  23. Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL . Long-term drug treatment of obesity in a private practice setting. Obes Res 1997; 5: 578–586.

    Article  CAS  Google Scholar 

  24. Yki-Jarvinen H, Nikkila K, Makimattila S . Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes. Drugs 1999; 58 (Suppl 1): 53–54.

    Article  CAS  Google Scholar 

  25. Makimattila S, Makimattila S, Nikkila K, Yki-Jarvinen H . Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999; 42: 406–414.

    Article  CAS  Google Scholar 

  26. De Fronzo RA, Goodman AM . Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541–549.

    Article  CAS  Google Scholar 

  27. Arslanian SA, Lewy V, Danadian K, Saad R . Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002; 87: 1555–1559.

    Article  CAS  Google Scholar 

  28. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM . Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels, in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 2767–2774.

    Article  CAS  Google Scholar 

  29. Lee A, Morley JE . Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998; 6: 47–53.

    Article  CAS  Google Scholar 

  30. Kay JP, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S . Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50: 1457–1461.

    Article  CAS  Google Scholar 

  31. Freemark M, Bursey D . The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: E55.

    Article  CAS  Google Scholar 

  32. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM . Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 8: 431–437.

    Article  CAS  Google Scholar 

  33. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J . Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1 year randomized double-blind study. Diabetes Care 1998; 21: 1288–1294.

    Article  CAS  Google Scholar 

  34. Pentikainen PJ, Voutilainen E, Aro A, Uusitupa M, Penttila I, Vapaatalo H . Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. Ann Med 1990; 22: 307–312.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology & Metabolism, School of Medicine, Akdeniz University, Turkey

    R Sari, M K Balci, E Coban & G Yazicioglu

Authors
  1. R Sari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M K Balci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Coban
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Yazicioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Sari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sari, R., Balci, M., Coban, E. et al. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes 28, 1059–1063 (2004). https://doi.org/10.1038/sj.ijo.0802707

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802707

Keywords

This article is cited by

Search

Advanced search

Quick links